Treatment pathway of bone sarcoma in children, adolescents, and young adults

Damon R. Reed, Masanori Hayashi, Lars Wagner, Odion Binitie, Diana A. Steppan, Andrew S. Brohl, Eric T. Shinohara, Julia A. Bridge, David M. Loeb, Scott C. Borinstein, Michael S. Isakoff

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

When pediatric, adolescent, and young adult patients present with a bone sarcoma, treatment decisions, especially after relapse, are complex and require a multidisciplinary approach. This review presents scenarios commonly encountered in the therapy of bone sarcomas with the goal of objectively presenting a consensus, multidisciplinary management approach. Little variation was found in the authors' group with respect to local control or systemic therapy. Clinical trials were universally prioritized in all settings. Decisions regarding relapse therapies in the absence of a clinical trial had very minor variations initially, but a consensus was reached after a literature review and discussion. This review presents a concise document and figures as a starting point for evidence-based care for patients with these rare diseases. This framework allows prospective decision making and prioritization of clinical trials. It is hoped that this framework will inspire and focus future clinical research and thus lead to new trials to improve efficacy and reduce toxicity. Cancer 2017;123:2206–2218.

Original languageEnglish (US)
Pages (from-to)2206-2218
Number of pages13
JournalCancer
Volume123
Issue number12
DOIs
StatePublished - Jun 15 2017
Externally publishedYes

Fingerprint

Sarcoma
Young Adult
Bone and Bones
Clinical Trials
Consensus
Recurrence
Therapeutics
Rare Diseases
Decision Making
Patient Care
Pediatrics
Research
Neoplasms

Keywords

  • adolescent and young adult (AYA)
  • chemotherapy
  • Ewing sarcoma
  • osteosarcoma
  • pathways
  • pediatric

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Reed, D. R., Hayashi, M., Wagner, L., Binitie, O., Steppan, D. A., Brohl, A. S., ... Isakoff, M. S. (2017). Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer, 123(12), 2206-2218. https://doi.org/10.1002/cncr.30589

Treatment pathway of bone sarcoma in children, adolescents, and young adults. / Reed, Damon R.; Hayashi, Masanori; Wagner, Lars; Binitie, Odion; Steppan, Diana A.; Brohl, Andrew S.; Shinohara, Eric T.; Bridge, Julia A.; Loeb, David M.; Borinstein, Scott C.; Isakoff, Michael S.

In: Cancer, Vol. 123, No. 12, 15.06.2017, p. 2206-2218.

Research output: Contribution to journalReview article

Reed, DR, Hayashi, M, Wagner, L, Binitie, O, Steppan, DA, Brohl, AS, Shinohara, ET, Bridge, JA, Loeb, DM, Borinstein, SC & Isakoff, MS 2017, 'Treatment pathway of bone sarcoma in children, adolescents, and young adults', Cancer, vol. 123, no. 12, pp. 2206-2218. https://doi.org/10.1002/cncr.30589
Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS et al. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 2017 Jun 15;123(12):2206-2218. https://doi.org/10.1002/cncr.30589
Reed, Damon R. ; Hayashi, Masanori ; Wagner, Lars ; Binitie, Odion ; Steppan, Diana A. ; Brohl, Andrew S. ; Shinohara, Eric T. ; Bridge, Julia A. ; Loeb, David M. ; Borinstein, Scott C. ; Isakoff, Michael S. / Treatment pathway of bone sarcoma in children, adolescents, and young adults. In: Cancer. 2017 ; Vol. 123, No. 12. pp. 2206-2218.
@article{914223173991432d8a8740236e76d7f3,
title = "Treatment pathway of bone sarcoma in children, adolescents, and young adults",
abstract = "When pediatric, adolescent, and young adult patients present with a bone sarcoma, treatment decisions, especially after relapse, are complex and require a multidisciplinary approach. This review presents scenarios commonly encountered in the therapy of bone sarcomas with the goal of objectively presenting a consensus, multidisciplinary management approach. Little variation was found in the authors' group with respect to local control or systemic therapy. Clinical trials were universally prioritized in all settings. Decisions regarding relapse therapies in the absence of a clinical trial had very minor variations initially, but a consensus was reached after a literature review and discussion. This review presents a concise document and figures as a starting point for evidence-based care for patients with these rare diseases. This framework allows prospective decision making and prioritization of clinical trials. It is hoped that this framework will inspire and focus future clinical research and thus lead to new trials to improve efficacy and reduce toxicity. Cancer 2017;123:2206–2218.",
keywords = "adolescent and young adult (AYA), chemotherapy, Ewing sarcoma, osteosarcoma, pathways, pediatric",
author = "Reed, {Damon R.} and Masanori Hayashi and Lars Wagner and Odion Binitie and Steppan, {Diana A.} and Brohl, {Andrew S.} and Shinohara, {Eric T.} and Bridge, {Julia A.} and Loeb, {David M.} and Borinstein, {Scott C.} and Isakoff, {Michael S.}",
year = "2017",
month = "6",
day = "15",
doi = "10.1002/cncr.30589",
language = "English (US)",
volume = "123",
pages = "2206--2218",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Treatment pathway of bone sarcoma in children, adolescents, and young adults

AU - Reed, Damon R.

AU - Hayashi, Masanori

AU - Wagner, Lars

AU - Binitie, Odion

AU - Steppan, Diana A.

AU - Brohl, Andrew S.

AU - Shinohara, Eric T.

AU - Bridge, Julia A.

AU - Loeb, David M.

AU - Borinstein, Scott C.

AU - Isakoff, Michael S.

PY - 2017/6/15

Y1 - 2017/6/15

N2 - When pediatric, adolescent, and young adult patients present with a bone sarcoma, treatment decisions, especially after relapse, are complex and require a multidisciplinary approach. This review presents scenarios commonly encountered in the therapy of bone sarcomas with the goal of objectively presenting a consensus, multidisciplinary management approach. Little variation was found in the authors' group with respect to local control or systemic therapy. Clinical trials were universally prioritized in all settings. Decisions regarding relapse therapies in the absence of a clinical trial had very minor variations initially, but a consensus was reached after a literature review and discussion. This review presents a concise document and figures as a starting point for evidence-based care for patients with these rare diseases. This framework allows prospective decision making and prioritization of clinical trials. It is hoped that this framework will inspire and focus future clinical research and thus lead to new trials to improve efficacy and reduce toxicity. Cancer 2017;123:2206–2218.

AB - When pediatric, adolescent, and young adult patients present with a bone sarcoma, treatment decisions, especially after relapse, are complex and require a multidisciplinary approach. This review presents scenarios commonly encountered in the therapy of bone sarcomas with the goal of objectively presenting a consensus, multidisciplinary management approach. Little variation was found in the authors' group with respect to local control or systemic therapy. Clinical trials were universally prioritized in all settings. Decisions regarding relapse therapies in the absence of a clinical trial had very minor variations initially, but a consensus was reached after a literature review and discussion. This review presents a concise document and figures as a starting point for evidence-based care for patients with these rare diseases. This framework allows prospective decision making and prioritization of clinical trials. It is hoped that this framework will inspire and focus future clinical research and thus lead to new trials to improve efficacy and reduce toxicity. Cancer 2017;123:2206–2218.

KW - adolescent and young adult (AYA)

KW - chemotherapy

KW - Ewing sarcoma

KW - osteosarcoma

KW - pathways

KW - pediatric

UR - http://www.scopus.com/inward/record.url?scp=85017149243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017149243&partnerID=8YFLogxK

U2 - 10.1002/cncr.30589

DO - 10.1002/cncr.30589

M3 - Review article

VL - 123

SP - 2206

EP - 2218

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -